Abstract
Abstract
The 2014 American Thyroid Association (ATA) guidelines on thyroid nodules and differentiated thyroid cancer use risk stratification based on patient and disease characteristics, including molecular markers, to inform the strategy for patient treatment and follow-up. Dr. Erik Alexander, a member of the task force, reviewed these changes in an ATA Satellite Symposium at the ICE/AACE Conference in June 2014, emphasizing the differences in the risk stratification systems used based on the type of risk that is assessed. He details the ways in which the AJCC/UICC system can be used to predict disease mortality, the ATA Initial Risk Stratification System to predict recurrence, and the ATA Response to Therapy System to evaluate changes in risk over time.
Runtime of video: 11 mins 51 secs
Original date of release on June 20, 2014, at ICE/AACE Conference in Chicago, Illinois.
Keywords
Get full access to this article
View all access options for this article.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
